TNFRSF18 and neoplasm: Because high GITR expression is mostly restricted to the tumor site, which potentially limits systemic adverse events of GITR targeting, in our opinion GITR represents an attractive target for therapeutic immunomodulation alone or in combination with ICB in these pMMR patients.